Pathological response across Lauren subtypes after neoadjuvant XELOX plus PD-1 blockade in locally advanced gastric cancer (KINGCA Week 2026) - Oct 11, 2026 - Abstract #PP-001; Pres time: Sep 18, 2026; 04:20 PM - 05:40 PM; Location: Sapphire 3+4; "The PD-1 inhibitor was toripalimab in 22 patients and nivolumab in 28. Neoadjuvant XELOX plus PD-1 blockade induced measurable responses in predominantly cT3–4 locally advanced gastric cancer. Although prior studies suggested greater sensitivity of intestinal-type tumors to neoadjuvant immunochemotherapy, this cohort showed favorable regression in a subset of diffuse-type tumors, suggesting a potential responsive subgroup within diffuse-type gastric cancer that warrants further validation."
Clinical • Metastases • Gastric Cancer • Oncology • Solid Tumor
|
|
Weixian Hu; Junjiang Wang; Yong Li
|